Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarogoulidis, Paul, Huang, Haidong, Tsiouda, Theodora, Sardeli, Chrysa, Trakada, Georgia, Veletza, Lemonia, Kallianos, Anastasios, Kosmidis, Christoforos, Rapti, Aggeliki, Papaemmanouil, Liana, Hatzibougias, Dimitrios, Drougas, Dimitrios, Bai, Chong, Hohenforst-Schmidt, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671388/
https://www.ncbi.nlm.nih.gov/pubmed/29124007
http://dx.doi.org/10.1016/j.rmcr.2017.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5671388/
https://www.ncbi.nlm.nih.gov/pubmed/29124007
http://dx.doi.org/10.1016/j.rmcr.2017.10.006

Ejemplares similares